10-Q/A: BioCardia Faces Going Concern, Nasdaq Delisting Risk

BioCardia, Inc. reports significant net losses and liquidity challenges, raising substantial doubt about its ability to continue operations beyond October 2025, alongside a Nasdaq non-compliance notice.

Summary

• BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
• The company incurred a net loss of $4.761 million for the six months ended June 30, 2025, compared to $3.913 million for the same period in 2024.
• Cash and cash equivalents decreased to $980,000 as of June 30, 2025, from $2.371 million at December 31, 2024.
• Accumulated deficit reached approximately $164.9 million as of June 30, 2025.
• The company's stockholders' equity moved to a deficit of $(1.886) million as of June 30, 2025, from a positive $837,000 at December 31, 2024.
• Research and development expenses increased to $2.898 million for the six months ended June 30, 2025, from $2.041 million in the prior year, driven by CardiAMP Heart Failure Trial closeout and CardiAMP Heart Failure II Trial enrollment.
• Net cash used in operating activities increased to $3.267 million for the six months ended June 30, 2025, from $2.842 million in the prior year.
• The company received a Nasdaq notice on April 1, 2025, for non-compliance with the minimum stockholders' equity requirement of $2.5 million, with an extension to regain compliance by September 29, 2025.
• BioCardia has conducted several capital raises, including private placements in April 2025 ($775,000 gross proceeds) and June 2025 ($570,000 gross proceeds), and ongoing At-the-Market (ATM) offerings, which generated $769,000 gross proceeds between July 1 and August 8, 2025.
• The CardiAMP Cell Therapy Heart Failure Trial (CardiAMP HF) showed statistically significant composite endpoint results in patients with elevated NTproBNP, with data submitted to Japan's PMDA and planned FDA submission in Q4 2025.
• The CardiAMP HF II Phase 3 trial for ischemic HFrEF has commenced patient randomization.
• The CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial's open-label roll-in cohort showed an average 107-second increase in exercise tolerance and an 82% average reduction in angina episodes at six months.
• The CardiALLO allogeneic MSC therapy for ischemic HFrEF Phase 1/2 trial's low-dose cohort completed with no treatment-emergent adverse events, and the Data Safety Monitoring Board recommended proceeding.
• The Helix transendocardial biotherapeutic delivery system is intended for DeNovo 510(k) FDA submission, and the Morph DNA steerable introducer platform received FDA market clearance.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a going concern warning, and Nasdaq non-compliance, indicating significant financial distress despite some positive clinical trial progress. The need for continuous, dilutive capital raises and the negative equity position are major concerns.

Positives

• Two-year results from the CardiAMP HF Trial showed reduction in all-cause death, reduced major adverse cardiac events, and improved quality of life, with a statistically significant composite endpoint in patients with elevated NTproBNP.
• The company has submitted CardiAMP HF data to Japan's PMDA and anticipates an in-person consultation in Q4 2025, potentially leading to market entry approval in Japan.
• The CardiAMP HF II Phase 3 trial has commenced patient randomization, with Medicare reimbursement (C9782, $17,500) helping offset study costs.
• The open-label roll-in cohort of the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial demonstrated an average 107-second increase in exercise tolerance and an 82% average reduction in angina episodes at six months.
• The low-dose cohort of the CardiALLO allogeneic MSC Phase 1/2 trial for ischemic HFrEF completed with no treatment-emergent adverse events, and the DSMB recommended proceeding.
• The Helix transendocardial biotherapeutic delivery system has a strong safety record with over 4,000 intramyocardial deliveries across twelve clinical studies, supporting a planned DeNovo 510(k) FDA application.
• The Morph DNA steerable introducer platform received FDA market clearance for an 8 French equivalent (AVANCE), enhancing physician control for cardiac procedures.
• A development, license, distribution, and option agreement was entered into with CART-Tech, B.V. for a fusion imaging system.

Negatives

• The company has incurred net losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $164.9 million as of June 30, 2025.
• Cash and cash equivalents of $980,000 as of June 30, 2025, are not sufficient to fund planned expenditures beyond October 2025, raising substantial doubt about the company's ability to continue as a going concern.
• Stockholders' equity moved to a deficit of $(1.886) million as of June 30, 2025, from a positive $837,000 at December 31, 2024.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million and faces a delisting risk if compliance is not regained by September 29, 2025.
• Net loss increased to $4.761 million for the six months ended June 30, 2025, compared to $3.913 million for the same period in 2024.
• Revenue was $0 for the six months ended June 30, 2025, a decrease from $58,000 in the prior year.
• Net cash used in operating activities increased to $3.267 million for the six months ended June 30, 2025, indicating an increased cash burn rate.
• The company relies heavily on continuous capital raises, which may lead to significant dilution for existing common stockholders.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern beyond October 2025 due to insufficient cash and ongoing operating losses.
• Failure to raise additional capital through debt, equity, or collaboration arrangements could force the company to reduce operating expenses, delay product development, relinquish technology rights, or cease operations.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement and faces potential delisting if it fails to regain compliance by September 29, 2025, which could decrease trading volume, share price, and ability to raise capital.
• Future equity offerings to raise capital will likely result in significant dilution for existing common stockholders.
• The success of therapeutic candidates is uncertain and depends on clinical trial progress, regulatory approvals, and commercialization capabilities, which require substantial future funding.
• The company's financial statements do not include any adjustments that might result from the outcome of the going concern uncertainty, and liquidation values could be significantly lower than book values.

Future Outlook

Management expects operating losses and negative cash flows to continue for at least the next several years, with increasing costs as clinical trials and development activities advance. The company anticipates needing additional funding beyond October 2025 and plans to raise capital through debt, equity, or collaboration arrangements. Regulatory submissions for CardiAMP Cell Therapy to Japan's PMDA and the FDA are expected in Q4 2025, with potential market entry in Japan. Phase 2 development for CardiALLO allogeneic MSC therapy is anticipated to advance in the United States and Japan within approximately one year, potentially followed by conditional approval in Japan.

Management Comments

• David McClung, Chief Financial Officer, certified that the Quarterly Report on Form 10-Q does not contain any untrue statement of a material fact or omit to state a material fact, and that the financial statements fairly present the financial condition, results of operations, and cash flows.
• Peter Altman, President and Chief Executive Officer, certified that the Quarterly Report on Form 10-Q fully complies with Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Industry Context

BioCardia operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on cell therapies and delivery systems for cardiovascular and pulmonary diseases. The company's strategy involves advancing multiple clinical programs (autologous and allogeneic cell therapies) and leveraging its Helix delivery platform through partnerships. The pursuit of FDA Breakthrough Device Designation and potential conditional approval in Japan for its therapies indicates a focus on high-unmet-need areas and accelerated regulatory pathways, common strategies for innovative biotech firms. The reliance on continuous capital raises and the going concern warning are typical challenges for clinical-stage companies without significant commercial revenue.

Legal Proceedings

• Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on the company's business, financial position, results of operations, or cash flows.

Related Party Transactions

• Certain of the company's directors and executive officers purchased an aggregate of 211,000 shares of Common Stock and accompanying Common Warrants in the September 2024 Registered Offering.
• Certain members of the board of directors and executive officers participated in the April 2025 private placement.
• Certain members of the board of directors and executive officers participated in the June 2025 private placement.

Stakeholder Impact

• Shareholders face significant risk of further dilution from ongoing and future capital raises.
• Shareholders face the risk of delisting from Nasdaq, which could negatively impact share price and liquidity.
• Employees and management face uncertainty regarding the company's ability to continue as a going concern.
• Patients and the medical community could potentially benefit from the advancement of the company's therapeutic candidates if clinical trials are successful and regulatory approvals are obtained.
• Creditors may face increased risk due to the company's precarious financial position and going concern warning.

Next Steps

• Complete submission of CardiAMP HF data and request a meeting with the FDA in Q4 2025 to discuss approvability of CardiAMP Cell Therapy for ischemic heart failure.
• Anticipate an in-person consultation with Japan's PMDA in Q4 2025 regarding CardiAMP system approval for market entry in Japan.
• Continue patient randomization and onboarding additional centers for the CardiAMP HF II Phase 3 trial.
• Prepare primary results of the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial's open-label roll-in cohort for publication and presentation.
• Advance Phase 2 development of CardiALLO allogeneic MSC therapy in both the United States and Japan, with anticipated enrollment in approximately one year.
• Potentially pursue conditional approval in Japan for CardiALLO after completion of the Phase 2 study, followed by a post-marketing study.
• Submit for approval of the Helix Transendocardial Delivery System to FDA as a DeNovo 510(k) application.
• Continue efforts to raise additional capital through debt, equity, or collaboration arrangements to fund operations beyond October 2025.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement by September 29, 2025, to avoid delisting.

Key Dates

Recommendation

The company's severe liquidity crisis, explicitly stating that cash is insufficient beyond October 2025, coupled with a formal 'going concern' warning, represents an immediate and critical threat to its viability. The Nasdaq non-compliance notice and the risk of delisting further exacerbate the situation, indicating a significant loss of investor confidence and potential for reduced trading liquidity. While clinical trial progress is noted, the financial instability and continuous, highly dilutive capital raises (including participation by insiders, which can be a mixed signal but here points to desperation) suggest that the company is in a precarious position. A seasoned investor would view these factors as overwhelmingly negative, indicating a high probability of substantial capital loss and recommending a strong sell.

Keywords

BioCardia, BCDA, SEC Filing, 10-Q/A, Quarterly Report, Financials, Going Concern, Nasdaq Delisting, Capital Raise, Clinical Trials, CardiAMP, Heart Failure, Refractory Angina, Cell Therapy, Biotherapeutic Delivery, Helix System, Morph DNA, Medical Devices, Biotechnology, Cardiology, MSC Therapy, ARDS